Drug‐associated glaucoma: A real‐world study based on the Food and Drug Administration adverse event reporting system database
Clinical & Experimental Ophthalmology · 2025
DOI: 10.1111/ceo.14454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Shi-Nan Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Glaucoma, United States Food and Drug Administration, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
This study aims to assess the risk of drug‐associated glaucoma and track its epidemiological characteristics using real‐world data.
Methods
Adverse event reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2023 were analysed. Disproportionality analysis and the Bayesian Confidence Propagation Neural Network algorithm were used. The study classified drugs associated with glaucoma, assessed risk levels, and compared drug‐induced times across different categories.
Results
Eight hundred and five drugs were linked to glaucoma in the FAERS database. Disproportionality analysis identified 46 drugs with significant risk, mainly adrenergic medications (clobetasol propionate, fluocinolone acetonide), antihypertensives (hydrochlorothiazide), insulin (insulin human), anticholinergics (umeclidinium, darifenacin), VEGF inhibitors (brolucizumab, faricimab), and psychotropics (topiramate, ziprasidone). The top three high‐risk drugs were clobetasol propionate, umeclidinium, and fluocinolone acetonide. The shortest drug‐induced times were observed with indacaterol, salmeterol, and umeclidinium. Anticholinergic medications had the shortest drug‐induced time among all categories. Females (62.5%) and the elderly (average age 63.5 ± 16.8 years) were predominantly affected. Reports of drug‐associated glaucoma increased over the years.
Conclusion
Preventing drug‐associated glaucoma is more effective than treatment. Identifying the risk and drug‐induced times of systemic and ophthalmic drugs can reduce occurrence risk. Clinical practitioners should be vigilant and inform patients of these risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen Universi…
- Institute of Artificial Intelligence, Xiamen University, Xiamen, China.
- Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen, China.
- Department of Ophthalmology, The First Affiliated Hospital of University of South China, Hengyang, China.
ORCID-Profile: Shi-Nan Wu, Shao-Pan Wang
Zitieren
APA
Wu, S. N., Chen, X. D., Yan, D., Wang, Y. Q., Wang, S. P., Guan, W. Y., Huang, C., Hu, J., & Liu, Z. (2025). Drug‐associated glaucoma: A real‐world study based on the Food and Drug Administration adverse event reporting system database. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14454
Vancouver
Wu SN, Chen XD, Yan D, Wang YQ, Wang SP, Guan WY, et al. Drug‐associated glaucoma: A real‐world study based on the Food and Drug Administration adverse event reporting system database. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14454
BibTeX
@article{Wu2025,
author = {Wu, Shi-Nan and Chen, Xiao-Dong and Yan, Dan and Wang, Yu-Qian and Wang, Shao-Pan and Guan, Wen-Ying and Huang, Caihong and Hu, Jiaoyue and Liu, Zuguo},
title = {Drug‐associated glaucoma: A real‐world study based on the Food and Drug Administration adverse event reporting system database},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
doi = {10.1111/ceo.14454}
}
EUVIMED